OncoMatch

OncoMatch/Breast Cancer/HER2 (ERBB2)

Breast CancerHER2 (ERBB2) Clinical Trials

141 recruiting trials·Updated daily from ClinicalTrials.gov

HER2 overexpression or amplification defines HER2-positive breast cancer — approximately 20% of cases — and predicts response to targeted therapy. Trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and neratinib (adjuvant) are approved across disease stages. Trials span neoadjuvant to metastatic settings and include HER2-low disease (IHC 1+ or 2+/FISH-negative), a recently validated therapeutic category.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting HER2 (ERBB2) Breast Cancer trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 3575 US sites

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

SWOG Cancer Research Network

Phase 377 US sites

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

BriaCell Therapeutics Corporation

Phase 351 US sites

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Greenwich LifeSciences, Inc.

Phase 320 US sites

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Hoffmann-La Roche

Phase 35 US sites

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Daiichi Sankyo

Phase 3

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

Shanghai Jiao Tong University School of Medicine

Additional trials

More HER2 (ERBB2) Breast Cancer trials

See all in search →
Phase 2
NCT04893109ATEMPT 2.0: Adjuvant T-DM1 vs THPhase 252 US sitesNCT06324357Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPhase 1/Phase 225 US sitesNCT07102381A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerPhase 224 US sitesNCT07007559ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerPhase 223 US sitesNCT06533826TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdPhase 211 US sitesNCT05570253A Study of SDX-7320 in Combination With Eribulin for People With Breast CancerPhase 210 US sitesNCT05559164Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 TargetedPhase 210 US sites
17 international trials (no US sites)
NCT06704945No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant ChemotherapyPhase 3NCT07003074A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerPhase 3NCT05838066Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.Phase 3NCT06643585A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapsePhase 3NCT05904964Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)Phase 3NCT05159193Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast CancerPhase 3NCT06839001CRYoablation for Small Tumors As Local Treatment - SIX TrialPhase 3NCT01785420Pre Operative Trastuzumab in Operable Breast CancerPhase 3NCT06079983JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsPhase 3NCT07294508A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerPhase 2/Phase 3NCT07019363CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)Phase 3NCT06313983A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast CancerPhase 3NCT05760612Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabPhase 3NCT03561740A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTientsPhase 3NCT07057427Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast CancerPhase 3NCT07008976Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerPhase 3NCT04646759Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast CancerPhase 3
Related therapies

FDA-approved therapies for HER2 (ERBB2) Breast Cancer

Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.

Trastuzumab DeruxtecanHER2-directed antibody-drug conjugateHER2-positive and HER2-low unresectable or metastatic breast cancer
Other Breast Cancer biomarkers

Browse other molecular targets with active Breast Cancer trials.

ESR1 (ER)PGR (PR)PIK3CABRCA1BRCA2
← All Breast Cancer clinical trials